Clinical & Translational

Qiagen posted revenues of $319.5 million compared to $330.8 million in the year-ago period, and beat analysts' consensus estimate on the top and bottom lines.

The firm increased its MDx revenues 7 percent from a year ago and beat the consensus Wall Street estimates on the top and bottom lines.  

Revenues for the Cambridge, Massachusetts-based company increased to $22.5 million in the second quarter from $ 14.5 million in Q2 2014.

The lightweight, mobile device was highlighted in an oral presentation at AACC today. 

The partners will try out the Ubiquitome Freedom4 hand-held, real-time PCR device in a range of quality assurance applications in food production and distribution.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.